Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ARQT - Arcutis: Roflumilast Has Excellent Data And High Probability Of FDA Approval

ARQT - Arcutis: Roflumilast Has Excellent Data And High Probability Of FDA Approval

Arcutis Biotherapeutics Inc.
  • Phase 3 data from the DERMIS Phase 3 trials demonstrated an excellent efficacy profile for roflumilast in psoriasis.
  • The side effect profile was also excellent.
  • Roflumilast has a PDUFA date in July and it is likely to be approved.
  • Peak sales may reach $1B in psoriasis.
  • Roflumilast is being tested in atopic dermatitis, seborrheic dermatitis and scalp psoriasis offering additional upside if data is favorable.

For further details see:

Arcutis: Roflumilast Has Excellent Data And High Probability Of FDA Approval
Stock Information
Company Name: Arcutis Biotherapeutics Inc.
Stock Symbol: ARQT
Market: NASDAQ
Website: arcutis.com
Menu
ARQT ARQT Quote ARQT Short ARQT News ARQT Articles ARQT Message Board
Get ARQT Alerts

News, Short Squeeze, Breakout and More Instantly...